

Houde CA, Khan A, Jacobus SJ, et al. Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus Rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the Determination phase 3 trial [abstract]. *Blood*. 2023;142(suppl 1):4762.

The first author of this American Society of Hematology Annual Meeting abstract, Christiane A. Houde, BS, should not be listed as an author. The first author should be Jeffrey A. Zonder, MD, with Karmanos Cancer Institute, Detroit, MI, as the affiliation. Under "Disclosures," the first author's disclosures should read "**Zonder:** Janssen, Prothena, Regeneron: Consultancy; Bristol-Myers Squibb/Celgene: Research Funding; Takeda, Telios: Other: Consultancy which has ended within the past 24 months."

<https://doi.org/10.1182/blood.2024025081>

© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]. *Blood*. 2023;142(suppl 1):7414.

The last author of this American Society of Hematology Annual Meeting abstract, Supreet Kaur, should not be listed as an author. The last author should be Zohra Nooruddin, MD, with University of Texas Health-San Antonio, San Antonio, TX, as the affiliation and no conflicts of interest to disclose.

<https://doi.org/10.1182/blood.2024025087>

© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.